Reduced intensity transplantation: where are we now?
Mackinnon
Stephen
S
Royal Free and University College London, London, UK.
Thomson
Kirsty
K
Morris
Emma
E
Kottaridis
Panagiotis D
PD
Peggs
Karl S
KS
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D001853:Bone Marrow / Q000187:drug effects / Q000528:radiation effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006086:Graft vs Host Disease / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000401:mortality / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology; D008212:Lymphocyte Depletion; D009190:Myelodysplastic Syndromes / Q000401:mortality / Q000628:therapy; D009503:Neutropenia / Q000209:etiology / Q000517:prevention & control; D055728:Primary Myelofibrosis / Q000401:mortality / Q000628:therapy; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D014184:Transplantation, Homologous / Q000276:immunology; D016896:Treatment Outcome; D014916:Whole-Body Irradiation / Q000009:adverse effects
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents